DIFFICULT CHOICE OF β-ADRENOBLOCKERS IN CLINICAL PRACTICE
- Authors: Bulanova E.1, Drapkina O.1, Popova I.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 23, No 8 (2012)
- Pages: 40-43
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115455
- ID: 115455
Cite item
Open Access
Access granted
Abstract
Β-Adrenoblockers (β-ABs) have proved their efficacy and relative safety. The basic effects of block of β-ABs located in all smooth muscle fibers, including those in the vessel wall, are antihypertensive, anti-ischemic, antioxidant, and antiarrhythmic. The lipophilic cardioselective β-blocker nebivolol holds a special place among β-ABs. There is evidence for its high efficacy in correcting endothelial dysfunction in patients with arterial hypertension and coronary heart disease and for its antiatherosclerotic properties associated with its ability to normalize the synthesis of endothelial nitric oxide.
Full Text
About the authors
E. Bulanova
I.M. Sechenov First Moscow State Medical UniversityCandidate of Medical Sciences
O. Drapkina
I.M. Sechenov First Moscow State Medical University
Email: drapkina@bk.ru
Professor, MD
I. Popova
I.M. Sechenov First Moscow State Medical UniversityCandidate of Medical Sciences
References
- Белоусов Ю.Б., Моисеев В.С, Лепахин В.К. Клиническая фармакология и фармакотерапия / М.: Универсум. - 1993; 397 с.
- Белоусов Ю.Б. Клиническая фармакология β-адреноблокаторов. Мат-лы XII научно-практ. конф. Московской ассоциации кардиологов «β-Адреноблокаторы: современные аспекты применения в кардиологии» / М., 1997.
- Марцевич С.Ю. Бета-адреноблокаторы: современные подходы к применению // Тер. арх. - 2002; 1 (74): 67-70.
- Марцевич С.Ю. Бета-адреноблокаторы: принципы терапии с позиций доказательной медицины // Кардиология. - 2002; 4 (42): 82-5.
- Шилов А.М., Мельник М.В., Авшалумов А.Ш. Бета-адреноблокаторы III поколения в лечении сердечно-сосудистых заболеваний // Лечащий врач. - 2010; 2: 7-12.
- Явелов И.С. Медикаментозное лечение инфаркта миокарда в подостром периоде заболевания и после выписки из стационара // Сердце: журнал для практикующих врачей. - 2022, 1 (1): 30-4.
- Avci E., Yeşil M., Bayata S. et al. The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction // Anadolu. Kardiyol. Derg. - 2011; 11 (7): 613-7.
- Devereaux P., Scott Beattie W., Choi P. et al. How strong is the evidence for the use of perioperative b-blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials // BMJ. - 2005; 331: 313-21.
- Elman M., Sugar J., Fiscella R. et al. The effect of propranolol versus placebo on resident surgical performance / Transactions of the American Ophthalmological Society. - 1998; 96: 283-91.
- Herlitz J., Dellborg М., Karlson B. et al. Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge // Cardiovasc. Drugs. Ther. - 2001; 14: 589-95.
- Gourine A., Bondar S., Spyer K. et al. Beneficial Effect of the Central Nervous System р-Adrenoceptor Blockade on the Failing Heart // Circ. Res. - 2008; 102: 633-6.
- Leinck J. In introduction to Cardiovascular Physiology / London: Butterworth. - 1991; 279 p.
- Mashford M., Collin H., Cooper M. et al. Analgesic. Therapeutic Guidelines / Therapeutic Guidelines Limited. - 2002; 488 p.
- Maggioni A. Review of the new ESC quidelines for the pharmacological management of chronic heart failure // Eur. Heart J. - 2005; 7: 15-21.
- Moser M., Sowers J. Clinical Management of Cardiovascular Risk Factors in Diabetes / 2nd ed. Caddo, Okla. - 2005; 288 p.
- Packer M Beta-adrenergic blockade in chronic heart failure principles, progress, and practice // Prog. Cardiovasc. Dis. - 1998; 41 (Suppl. 1): 39-52.
- Packer M., Bristow M., Cohn J. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure // N. Engl. J. Med. - 1996; 334: 1349-55.
- Reeves R., Boer W., DeLeve L. et al. Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity // Clin. Pharmacol. Ther. - 1989; 46: 279-90.
- Tendera M. Epidemiology, treatment and quidelines for the treatment of heart failure in Europe // Eur. Heart J. - 2005; 7: 5-10.
- Tse W., Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? // Diabet. Med. - 1994; 11: 137-44.
Supplementary files
